Introduction
Patients of African origin still bear the heaviest burden of the HIV pandemic. 1 These patients have absolute peripheral blood CD4 lymphocyte counts similar to those of Caucasian patients 2 , but significant immunological discrepancies have been seen in patients of African origin. 3 During the natural course of HIV infection, the CD4+ count decreases more slowly in patients of African origin than in Caucasian patients. 4 Previous studies have found the CD4+ count increase with highly active antiretroviral therapy (HAART) not to be significantly different between HIV-infected patients of African origin and HIV-infected Caucasian patients. 5 Only one investigation has reported evidence of a greater CD4+ count increase in Caucasian patients compared to patients of African origin during the first months of HAART. 6 Discrepancies between these studies could be linked to the low number of patients of African origin compared to the Caucasian patients, to the various geographic origins of patients of African origin, and to the time delay between the diagnosis of HIV infection and the initiation of HAART, as well as the potential impact of HIV-1 subtypes. 7 The effect of ethnicity on the CD4 immune reconstitution during HAART remains an unsolved question, the answer to which could be of major interest. We conducted a retrospective epidemiological investigation to assess whether African ethnicity is independently associated with a poorer CD4 reconstitution during HAART.
hospital center (France), who gave informed consent for the digitization of their medical records using Nadis software, were included.
Socio-demographic, clinical, and immuno-virological data (HIV-1 subtype, CD4+ count, and HIV-1 viral loads at baseline and during follow-up at 6, 9, 12, 18, 24, 36 , and 48 months after beginning HAART) were extracted from Nadis. This database has been declared to the Commission Nationale Informatique et Liberté (number 1585477).
The baseline CD4+ count was defined as the lowest absolute value before HAART. Immunological success (IS) was defined as the presence of a CD4+ count >500 cells/mm 3 in more than 50% of the values collected during follow-up. 8 Age, US Centers for Disease Control and Prevention (CDC) classification category B or C, and HIV-1 viral load at baseline were those extracted before the first line of HAART in patients with multiple lines of therapy. The last line was considered for immunovirological data collection during follow-up, except when a previous line had lasted more than 48 months without any significant HIV-1 viral load variations (see exclusion criteria described below).
In accordance with the ANRS (Agence Nationale de Recherche sur le SIDA et les Hé patites Virales) algorithm, 9 HIV-1 subtype was defined as non-B in the presence of mutations at positions 35, 36, 61, 69, and 89 during routine pol gene sequencing.
The following patients were excluded: those displaying an HIV-1 viral load >20 copies/ml (TaqMan, Roche) 6 months after beginning HAART and those displaying an HIV-1 viral load >200 copies/ml, or more than one HIV-1 viral load between 20 and 200 copies/ml, from 9 to 48 months after beginning HAART. Patients lost to follow-up, with a duration of follow-up less than 9 months, and patients with a baseline CD4+ count >500 cells/mm 3 were also excluded.
Statistical analysis
Quantitative variables were compared using the Mann-Whitney U-test and qualitative variables were compared using Fisher's exact test or Pearson's Chi-square test, as appropriate. A pvalue of <0.05 was considered significant. All variables with a pvalue of <0.20 were entered into a multiple logistic regression model. Statistical analyses were performed using StatView 5.0 software (SAS Institute, Cary, NC, USA).
Results
Two hundred and twenty (78.6%) Caucasian patients and 60 (21.4%) patients of African origin met the inclusion criteria and none of the exclusion criteria ( Figure S1 ).
At 36 and 48 months after initiation of HAART, CD4+ counts were different between patients of African origin (n = 38 and 31) and Caucasian patients (n = 167 and 148): 469 (93-677) vs. 528 (45-1383) at 36 months (p = 0.03), and 449 (65-975) vs. 569 (131-1698) cells/mm 3 at 48 months (p = 0.02). CD4+ count reconstitution (Table 1) . dynamics are depicted in Figure 1A for the 177 patients with CD4+ counts available at baseline and at 48 months. The CD4 increase slope appeared to be steeper in Caucasian patients than in patients of African origin, but this was without statistical significance (p = 0.09). Eighty-seven of the 150 Caucasian patients and only 10 of the 27 patients of African origin had a CD4+ count >500/mm 3 at 48 months (p = 0.04).
Immunological success was present in 142 of the 220 Caucasian patients (64.5%) vs. 29 of the 60 patients of African origin (48.3%) (p = 0.02). Variables significantly associated with the absence of immunological success are depicted in Figure 1B . African ethnicity was independently associated with the absence of immunological success (odds ratio 2.22, 95% confidence interval 1.097-4.504; p = 0.02). African origin continued to be independently associated with the absence of immunological success after adjustment for age and even when immunological success was defined as the presence of a CD4+ count >500 cells/mm 3 twice during follow-up (data not shown). Among the 177 patients with CD4+ counts available at baseline and up to 48 months after beginning HAART, immunological success was present in 10 out of the 27 patients of African origin (37.0%) vs. 102 out of the 150 Caucasian patients (68.0%) (p = 0.002).
Discussion
In the present study, CD4+ counts were found to be significantly lower in patients of African origin than in Caucasian patients at 36 and 48 months after the initiation of HAART. Rates of patients with CD4+ counts >500 cells/mm 3 at 48 months were also significantly lower in patients of African origin than in Caucasian patients, whereas baseline CD4+ counts were not significantly different between the two patients groups. Both the use of drastic exclusion criteria designed to rule out lack of adherence to HAART and our patients of African origin group mainly originating from West Africa and accounting for 20% of study patients, allowed us to properly assess the dynamics of CD4+ count recovery according to ethnicity. However our results could be linked to the small number of patients of African origin at 48 months and to an insufficient duration of follow-up. In our study, follow-up was stopped at 48 months because this time was considered as the time of steadystate for CD4+ count recovery. 10 Because we observed that patients of African origin have a lesser propensity to reach CD4+ counts >500 cells/mm 3 and because that threshold value is known to be correlated with a life-expectancy similar to that of the general population, 8 we assessed whether our immunological success criteria were independently associated with African ethnicity. Using our criteria, African ethnicity was the only factor independently associated with the absence of immunological success, except the baseline CD4+ count, which has been described previously. 5, 10 The effect of HIV-1 subtype non-B could not be excluded because of collinearity. In any case, taking all these results together, we could ask ourselves whether patients of African origin should not be treated earlier in order to definitely obtain a CD4+ count >500 cells/mm 3 . 8 Such early treatment could be justified only if we have first demonstrated that survival of patients of African origin is the same as in the general population, after adjustment for confounding factors such as HIV-1 subtype non-B, which has been associated once with a better immunological outcome in a different study setting. 7 Compared to this previous study, which was designed to focus on the modelization of the CD4+ increase slope of non-B HIV-1 HAART-treated patients at the primary infection stage, our retrospective investigation was designed to focus on the propensity of HAART-treated African patients to restore their CD4+ count >500 cells/mm 3 during the 48 months following the beginning of HAART. Such design discrepancies could explain the differences in results obtained in the previous study and ours.
In conclusion, our findings suggest that African ethnicity is independently associated with a poorer CD4 reconstitution during HAART than Caucasian ethnicity. Further prospective studies with larger numbers of patients of African origin and a follow-up longer than 48 months would be of major interest.
